


-42-

WHAT IS CLAIMED IS:

1. An isolated peptide of the general formula:



wherein

- 5 G is glutamate or glutamine;

- 10 X_1 is a bond or an amino acid selected from the group consisting of
glycine, alanine, valine, leucine, isoleucine, proline,
phenylalanine, tyrosine, tryptophan, cysteine, methionone,
serine, threonine, lysine, arginine, histidine, aspartate,
glutamate, asparagine, and glutamine;

- 15 X_2 is an amino acid selected from the group consisting of glycine,
alanine, valine, leucine, isoleucine, proline, phenylalanine,
tyrosine, tryptophan, cysteine, methionone, serine, threonine,
lysine, arginine, histidine, aspartate, glutamate, asparagine,
and glutamine, and

R is a tripeptide wherein at least one amino acid of said tripeptide is
selected from the group consisting of valine, leucine,
isoleucine, phenylalanine, tyrosine, and tryptophan.

2. A peptide according to claim 1, wherein:

- 20 X_1 is a bond, and

R is a tripeptide wherein only one amino acid of said tripeptide is
selected from the group consisting of valine, leucine,
isoleucine, phenylalanine, tyrosine, and tryptophan.

3. A peptide according to claim 1, wherein:

- 25 X_1 is a bond, and

-43-

R is a tripeptide wherein two amino acids of said tripeptide are independently selected from the group consisting of valine, leucine, isoleucine, phenylalanine, tyrosine, and tryptophan.

4. A peptide according to claim 1, wherein:
 - 5 X₁ is a bond, and
R is a tripeptide wherein each of the amino acids of said tripeptide are independently selected from the group consisting of valine, leucine, isoleucine, phenylalanine, tyrosine, and tryptophan.
5. A peptide according to claim 4, wherein X₂ is proline.
- 10 6. A peptide according to claim 1, wherein said peptide is selected from the group consisting of:
Glutamate—Proline—Leucine—Tyrosine—Isoleucine;
Glutamate—Proline—Leucine—Tyrosine—Valine;
Glutamate—Proline—Leucine—Phenylalanine—Isoleucine; and
15 Glutamate—Proline—Leucine—Phenylalanine—Valine.
7. A composition comprising a peptide according to claim 1 and a carrier therefor.
8. An isolated antibody to a peptide according to claim 1.
9. An antibody according to claim 8, wherein said antibody is a
20 monoclonal antibody.
10. An antibody according to claim 8, wherein said antibody is 6C5

-44-

11. An antibody according to claim 8, wherein said antibody is produced by the cell line F6-6C5-H4.
12. An antibody according to claim 8, wherein said antibody is a polyclonal antibody.
- 5 13. The cell line F6-6C5-H4.
14. A method of treating a yeast infection in a patient in need of such treatment comprising administering to said patient a composition comprising an active agent, wherein said active agent is an antibody according to claim 8.
- 10 15. A method of detecting a hydrophobic binding domain in a sample containing multiple components, comprising the steps of:
providing an antibody according to claim 8, wherein said antibody is labeled with a detectable marker;
contacting the sample with an antibody according to claim 8; and
15 isolating any resulting complexes formed between the sample components and the labeled antibodies.
16. The method of claim 15 wherein said detection is performed *in vivo*.
17. The method of claim 15 wherein said detection is performed *in vitro*.
18. A method of isolating a hydrophobic binding domain comprising the steps of:
20

-45-


providing an antibody according to claim 8, wherein said antibody is labeled with a detectable marker, and wherein said antibody is bound to a solid support;

contacting a sample containing multiple components with said antibody; and

washing the solid support to remove unbound material.

19. A method of treating a yeast infection in a patient in need of such treatment comprising administering to said patient a composition comprising an active agent, wherein said active agent is

a peptide of the general formula:



wherein

G is glutamate or glutamine;

X_1 is a bond or an amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, cysteine, methionone, serine, threonine, lysine, arginine, histidine, aspartate, glutamate, asparagine, and glutamine;

X_2 is an amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, cysteine, methionone, serine, threonine, lysine, arginine, histidine, aspartate, glutamate, asparagine, and glutamine, and

R is a tripeptide wherein at least one amino acid of said tripeptide is selected from the group consisting of

-46-

valine, leucine, isoleucine, phenylalanine, tyrosine, and tryptophan.

20. A method according to Claim 19 wherein
X₁ is a bond, and
5 R is a tripeptide wherein one amino acid of said tripeptide is selected
from the group consisting of valine, leucine, isoleucine,
phenylalanine, tyrosine, and tryptophan.
21. A method according to claim 19 wherein said active agent is
introduced orally.
- 10 22. A method according to claim 19 wherein said active agent is
introduced intravenously.
23. A method according to claim 19 wherein said active agent is applied
topically.
24. An isolated peptide of the general formula:
15
$$E-X_1-L-X_2-X_3-X_4$$

wherein
E is glutamate;
X₁ is an amino acid selected from the group consisting of proline,
lysine, and glutamate;
20 X₂ is an amino acid selected from the group consisting of
phenylalanine and tyrosine;
X₃ is an amino acid selected from the group consisting of isoleucine
and valine; and

-47-

X₄ is an amino acid selected from the group consisting of serine and threonine.

25. A composition comprising a peptide according to claim 23 and a carrier therefor.
- 5 26. An isolated antibody to a peptide according to claim 23.
27. An antibody according to claim 25, wherein said antibody is a monoclonal antibody.
28. An antibody according to claim 26, wherein said antibody is 5D8.
29. An antibody according to claim 26, wherein said antibody is produced
10 by the cell line F6-5D8-A12.
30. An antibody according to claim 25, wherein said antibody is a polyclonal antibody.
31. The cell line F6-5D8-A12.
32. A method of treating a yeast infection in a patient in need of such
15 treatment comprising administering to said patient a composition comprising an active agent, wherein said active agent is an antibody according to claim 25.
33. A method of detecting a hydrophobic binding domain in a sample containing multiple components, comprising the steps of:

-48-

providing an antibody according to claim 25, wherein said antibody is
labeled with a detectable marker;
contacting the sample with an antibody according to claim 25; and
isolating any resulting complexes formed between the sample
5 components and the labeled antibodies.

34. The method of claim 33 wherein said detection is performed *in vivo*.

35. The method of claim 33 wherein said detection is performed *in vitro*

36. A method of isolating a hydrophobic binding domain comprising the
steps of:

10 providing an antibody according to claim 25, wherein said antibody is
labeled with a detectable marker, and wherein said antibody is
bound to a solid support;
contacting a sample containing multiple components with said
antibody; and
15 washing the solid support to remove unbound material.

37. A method of treating a yeast infection in a patient in need of such
treatment comprising administering to said patient a composition comprising
an active agent, wherein said active agent is
peptide of the general formula:

20
$$\text{E-X}_1\text{-L-X}_2\text{-X}_3\text{-X}_4$$

wherein

E is glutamate;

X₁ is an amino acid selected from the group consisting of proline,
lysine, and glutamate;

-49-

X₂ is an amino acid selected from the group consisting of
phenylalanine and tyrosine;

X₃ is an amino acid selected from the group consisting of isoleucine
and valine; and

5 X₄ is an amino acid selected from the group consisting of serine and
threonine.

38. A method according to claim 37 wherein said active agent is
introduced orally.

10 39. A method according to claim 37 wherein said active agent is
introduced intravenously.

40. A method according to claim 37 wherein said active agent is applied
topically.

41. An isolated 5F8 antibody.

15 42. An antibody according to claim 41, wherein said antibody is produced
by the cell line F6-5F8-E10.

43. The cell line F6-5F8-E10.

20 44. A method of treating a yeast infection in a patient in need of such
treatment comprising administering to said patient a composition comprising
an active agent, wherein said active agent is an antibody according to claim
41.

-50-

45. A method of detecting a hydrophobic binding domain in a sample containing multiple components, comprising the steps of:
- providing an antibody according to claim 41, wherein said antibody is labeled with a detectable marker;
- 5 contacting the sample with an antibody according to claim 41; and isolating any resulting complexes formed between the sample components and the labeled antibodies.
46. The method of claim 45 wherein said detection is performed *in vivo*.
47. The method of claim 46 wherein said detection is performed *in vitro*.
- 10 48. A method of isolating a hydrophobic binding domain comprising the steps of:
- providing an antibody according to claim 41, wherein said antibody is labeled with a detectable marker, and wherein said antibody is bound to a solid support;
- 15 contacting a sample containing multiple components with said antibody; and washing the solid support to remove unbound material.